Weekly Recap | Abbvie -0.58%, most brokers rate it buyWeekly Review·Oct 3, 2026 at 08:26 AMABBV+0.35%
Weekly Recap | Eli Lilly -3.43%, most brokers rate it buyWeekly Review·Oct 3, 2026 at 07:08 AMLLY+1.26%LLYX+2.37%
Weekly Recap | Johnson & Johnson -5.6%, most brokers rate it buyWeekly Review·Oct 3, 2026 at 07:01 AMJNJ+0.73%
Weekly Recap | Gilead Sciences -4.1%, sliding toward range lowsWeekly Review·Oct 3, 2026 at 06:52 AMGILD-0.28%
Weekly Recap | AMGN.US -2.79%, consensus target above spotWeekly Review·Oct 3, 2026 at 06:18 AMAMGN-0.09%
Weekly Recap | Eli Lilly +2.65%, closing in on record highsWeekly Review·Sep 26, 2026 at 06:38 AMLLY+1.26%LLYX+2.37%
Weekly Recap | Johnson & Johnson +0.46%, most brokers rate it buyWeekly Review·Sep 26, 2026 at 06:33 AMJNJ+0.73%
Weekly Recap | Gilead Sciences +0.55%, consensus target above spotWeekly Review·Sep 26, 2026 at 06:25 AMGILD-0.28%
Weekly Recap | Abbvie +0.14%, FDA approves Parkinson's drugWeekly Review·Sep 26, 2026 at 05:51 AMABBV+0.35%
Weekly Recap | Johnson & Johnson +1.66%, most brokers rate it buyWeekly Review·Sep 19, 2026 at 06:18 AMJNJ+0.73%
Weekly Recap | Abbvie +2.66%, closing in on record highsWeekly Review·Sep 19, 2026 at 05:30 AMABBV+0.35%
Weekly Recap | Abbvie +0.26%, most brokers rate it buyWeekly Review·Sep 12, 2026 at 07:40 AMABBV+0.35%
